SCHEMBL10088295

SCHEMBL10088295

N[C@@H](CCCN(CC(=O)O)CC(=O)O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 5/20 0.51
▸ NOS3 P29474 3/20 0.51
▸ NOS1 P29475 3/20 0.51
▸ GSR P00390 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ EYA2 O00167 1/20 0.50
▸ APP P05067 1/20 0.50
▸ ACE P12821 1/20 0.50
▸ CYP1A2 P05177 2/20 0.48
▸ GRM8 O00222 1/20 0.48
▸ GRM6 O15303 1/20 0.48
▸ GRIN2D O15399 1/20 0.48
▸ GRIN3B O60391 1/20 0.48
▸ GRIK1 P39086 1/20 0.48
▸ GRM5 P41594 1/20 0.48
▸ GRIA1 P42261 1/20 0.48
▸ GRIA2 P42262 1/20 0.48
▸ GRIA3 P42263 1/20 0.48
▸ SLC1A3 P43003 1/20 0.48
▸ SLC1A2 P43004 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2305699 0.94 GSR (0.53) NOS2NOS3NOS1GSRTDP1
SCHEMBL158633 0.94 GSR (0.53) NOS2NOS3NOS1GSRTDP1
SCHEMBL10088294 0.92 GSR (0.52) NOS2NOS3NOS1GSRTDP1
Water SCHEMBL1336386 0.92 GSR (0.52) NOS2NOS3NOS1GSRTDP1
SCHEMBL7166178 0.92 GSR (0.52) NOS2NOS3NOS1GSRTDP1
SCHEMBL5613110 0.91 TDP1 (0.50) NOS2NOS3NOS1GSRTDP1
SCHEMBL10088260 0.88 TDP1 (0.54) NOS2NOS3NOS1GSRTDP1
Edetic Acid SCHEMBL4385396 0.87 GSR (0.60) NOS2NOS3NOS1GSRTDP1
Edetic Acid SCHEMBL4385387 0.87 GSR (0.60) NOS2NOS3NOS1GSRTDP1
SCHEMBL17690553 0.86 GSR (0.46) NOS2NOS3NOS1GSRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012432-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2013-01-10 — — US disclosed
US-20130012432-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2013-01-10 — — US disclosed
US-20120021973-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2012-01-26 — — US disclosed
US-20120021973-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2012-01-26 — — US disclosed
WO-2011104378-A1 PEPTIDES FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2011-09-01 — — WO disclosed
WO-2011104379-A1 PEPTIDES FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2011-09-01 — — WO disclosed
US-20100173835-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2010-07-08 — — US disclosed
US-20100173835-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2010-07-08 — — US disclosed
WO-2010060901-A1 PEPTIDES FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2010-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120021973-A1 Peptides for Treatment of Obesity MC4R, GIPR, MC3R NOS2 2387/4885NOS3 1555/4885NOS1 2334/4885
US-20100173835-A1 Peptides for Treatment of Obesity MC4R, GIPR, MC3R NOS2 2387/4885NOS3 1555/4885NOS1 2334/4885
US-20130012432-A1 Peptides for Treatment of Obesity MC4R, GIPR, MC3R NOS2 2387/4885NOS3 1555/4885NOS1 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback